[ad_1]
The drug regulator in Europe said today, Thursday (July 22, 2021) that it has added a rare neurological disorder known as Guillain-Barré syndrome as a possible side effect of the Johnson & Johnson vaccine against Covid-19, after examining 108 registered cases worldwide.
The European Medicines Agency (EMA) said: “After evaluating the available data, the safety committee concluded that there may be an association between Johnson & Johnson’s vaccine to prevent Covid-19 disease and Guillain-Barré syndrome. “
The same agency said last May that it was examining reports of a rare disorder of nervous disorders in people who have received anti-Covid-19 doses of AstraZeneca, at a time when authorities around the world are seeking transparency on the safety of coronavirus vaccines.
Guillain-Barré syndrome is a rare neurological disease in which the body’s immune system attacks the protective sheath of nerve fibers. Most of these cases occur after a microbial or viral infection.
According to the Mayo Clinic website, the first symptoms of this syndrome are weakness and numbness in the extremities, and these symptoms can spread to the whole body, which can lead to paralysis and should be urgently transferred to the hospital.
And the United States Food and Drug Administration warned of the syndrome after taking the Johnson-and-Johnson vaccine, and reported a few days ago that there were at least 100 people infected with it on more than 12.5 million who received this vaccine, and one of the infected died.
Johnson & Johnson said earlier that “the chances of this happening are very low and the rate of reported cases is only slightly above the base rate for the general population.”
In its warning, the United States Food and Drug Administration said that in the vast majority of people who developed the syndrome, symptoms began to appear within 42 days of receiving the vaccine.
AA / AH (Reuters)
-
Different nationalities .. Discover the most famous approved vaccines in the world
Biontech / Pfizer vaccine
Developed by the German Piontech jointly with the American Pfizer. Its effectiveness, according to the latest clinical trials, is 95 percent. It is the first corona vaccine authorized by the World Health Organization. It is based on mRNA technology and is the most widely used vaccine in the Western world, but it has been criticized for how difficult it is to store it because it has to be at minus 70 degrees Celsius to maintain its effectiveness.
-
Different nationalities .. Find out more about the most famous authorized vaccines in the world
Moderna
The second vaccine to be authorized by the European Union after Pfizer / Biontech. Developed by the American company Moderna in cooperation with the United States National Institutes of Health for Infectious Diseases. Its efficiency reached 95 percent. It adopts almost the same technology (mRNA), but its storage conditions are less strict and it needs minus 20 degrees. Despite this, the quantities of its worldwide distribution remained lower than the first vaccine, which can be explained by its price of $ 33 per dose, unlike the second vaccine of $ 20.
-
Different nationalities .. Find out more about the most famous authorized vaccines in the world
Sputnik V
It is the first vaccine in the world whose developers announce its effectiveness against Corona, even if it had not yet passed the third stage. It was developed by the Russian State Aesthetic Institute, and its efficiency reaches 92%, according to Russian figures, but with Western scientific hesitation due to the lack of published data about it. It has been imported by several countries, including Hungary, Algeria, Serbia and the United Arab Emirates. It’s easy to carry and inexpensive ($ 10) and uses adenovirus (or adenovirus) vector technology.
-
Different nationalities .. Discover the most famous approved vaccines in the world
AstraZeneca / Oxford
The second vaccine authorized by the World Health Organization and the third for the European Union. The cheapest vaccines, but also the least effective (70%), and many countries have questioned its effectiveness against the elderly, as well as against mutated versions. Developed by the Anglo-Swedish company AstraZeneca in cooperation with the University of Oxford. It was imported by several countries after the contribution of the Serum Institute of India to its production. It is easy to transport and store and it also uses glandular conveyor technology.
-
Different nationalities .. Find out more about the most famous authorized vaccines in the world
Sinopharm
Developed by Chinese state-owned company Sinopharm with the Beijing Institute of Biologics. It was first introduced by the United Arab Emirates before China allowed it, and then it was imported by several countries including Morocco, Jordan and Egypt. According to its manufacturers, its effectiveness rate has reached 79%, but the scientific data is not published correctly. It uses the inactivated virus injection technique, and the biggest mystery surrounding it is its price, as several reports have indicated that the dose is not less than $ 30, while others have mentioned a price. lower or higher.
-
Different nationalities .. Find out more about the most famous authorized vaccines in the world
Coronavac
It was produced by the Chinese company Sinovac, but its license in China took longer. Its effectiveness is controversial, as tests in Brazil have shown it to be no more than 51%, but other tests in Turkey, which was among the first to allow it, have increased its effectiveness to 91%. It uses the same technology as the Sinopharma vaccine, and there are many questions surrounding it due to lack of data, including its price, which has not been released, although reports put it at ten dollars.
-
Different nationalities .. Find out more about the most famous authorized vaccines in the world
Johnson & johnson
It was developed by the American company “Johnson & Johnson”, and South Africa began to use it, although it was not licensed in the United States or Europe, after discovering that he was able to cope with the mutated version, contrary to what was shown by the first experiments. Its efficiency reaches 66% in the world and 72 percent in America. It differs from others in that it is a single dose, which further enhances its chances of spread. It uses adenoviral vector technology and is easy to store.
[ad_2]
Source link
